Latest Market Entry News

Neurizon Therapeutics has been granted a pivotal US patent for its lead drug candidate NUZ-001, extending protection until 2039 and enhancing its commercial and clinical positioning in neurodegenerative disease treatment.

Argent BioPharma reports strategic cost-cutting moves including facility closures and delisting from the LSE, while securing German distribution approval and raising significant capital to support its drug pipeline.

Environmental Clean Technologies Limited has formed a joint venture and launched field trials for its innovative COLDry lignite-nitrogen fertiliser, marking a pivotal step toward commercialisation and revenue generation.

Cardiex has kicked off deliveries of its CONNEQT Pulse arterial health monitors in the U.S., reporting strong preorder momentum and a 150% sales increase in December. The company’s strategic operational shifts and pharma partnerships set the stage for sustained growth in 2025.

Pursuit Minerals has reported a remarkable 339% increase in lithium resources at its Rio Grande Sur project in Argentina, alongside plans to commence lithium carbonate production by Q1 2025. The company is also actively pursuing acquisitions and reviewing its gold assets amid tight cost controls.

Ovanti Limited has made significant strides in its plan to enter the US Buy Now Pay Later market, delivering a comprehensive strategic report and strengthening its executive team to support expansion.

HALO Technologies reports a robust 45.5% increase in operating revenue for 2024, driven by surging Funds Under Management and brokerage income, while advancing its UK market entry alongside a $6.75 million capital raise.

Echo IQ confirms the material significance of its pre-submission FDA meeting for EchoSolv HF, marking a pivotal step toward US market entry and commercialisation.

Wellnex Life Limited reported a 36% rise in Q2 FY25 cash receipts and record monthly sales, while advancing its dual listing on the London Stock Exchange and expanding into the UK market.

Cambium Bio has secured a A$3 million capital raise and achieved FDA Fast Track status for its lead ophthalmology product, Elate Ocular®, setting the stage for Phase 3 trials in mid-2025.

Oakridge International Limited reports a strong quarterly performance driven by increased contracted orders, strategic partnerships, and technological innovation, positioning the company for sustained growth into 2025.

RooLife Group Ltd (ASX:RLG) reports a remarkable 144% jump in Q2 FY25 sales revenue, driven by new online stores and strategic market entries into China and India. The company’s own branded health and wellness products are central to its growth strategy.